Aquestive Therapeutics is a specialty pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. We have a commercial product, Sympazan® (clobazam), and a late-stage proprietary product pipeline focused on advancing treatments for CNS diseases, as well as early-stage investigational assets that may replace invasively-administered standard of care therapies. Aquestive also collaborates with pharmaceutical partners to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®.
Access a comprehensive collection of financial information about Aquestive. Download current and previous SEC filings, including earnings releases, and quarterly and annual reports.
Join upcoming meetings and listen to past sessions that review the Aquestive business landscape, including sales performance and objectives, product-development activities, and the status of strategic partnerships.
PharmFilm® technology and Aquestive's development expertise has created a robust, proprietary CNS and complex molecule portfolio. See the expanding collection of medicines designed to overcome barriers that the patients face.